Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that its immunotherapeutic vaccine called Rindopepimut showed positive results in prolonging survival in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB), one of the most aggressive forms of brain cancer...
No comments:
Post a Comment